Effect of SugarLock® Peanut Skin Extract on Postprandial Blood Glucose Control
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTCI Co., Ltd.
About this trial
The objective of this study is to investigate the effects of pre-meal supplementation with SugarLock® peanut skin extract and white kidney bean extract on reducing or delaying postprandial blood glucose elevation and glycemic fluctuations, and to evaluate their potential as nutritional supplements for postprandial glycemic management.
Eligibility criteria
Qualifiers
Adults aged 18 years or older;
Fasting blood glucose level < 100 mg/dL;
Individuals without type 1 or type 2 diabetes.
Disqualifiers
Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
Individuals with chronic gastrointestinal diseases (such as irritable bowel syndrome [IBS], inflammatory bowel disease [IBD], chronic diarrhea, celiac disease, short bowel syndrome, ulcers, colorectal cancer, etc.), a history of epilepsy or seizures, psychiatric disorders, malignant tumors, endocrine disorders, liver or kidney disease, or other major organic diseases;
Individuals with a history of gastrointestinal surgery or organ transplantation;
Individuals who have taken medications or supplements affecting blood glucose or insulin within the past three months;
Trial design
Treatments tested in this trial
- Peanut skin extract
- White kidney bean extract
- Water
Treatment groups
30 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov